IgA nephropathy (Berger’s disease)

IgA nephropathy (Berger’s disease)

Definition:

A kidney disorder characterized by blood in the urine; caused by inflammation of the internal kidney structures and deposits of IgA antibodies in the kidney mesangial tissue.

Alternative Names:

Nephropathy - IgA; Berger's disease

Causes, incidence, and risk factors:

IgA nephropathy (Berger's disease) is a form of mesangial proliferative nephritis. Inflammation of the renal glomeruli occurs, and there are IgA (a type of antibody) deposits in the kidney. The disorder can appear as acute, rapidly progressive, or chronic glomerulonephritis; or as visible or microscopic hematuria (blood in the urine).

Berger's disease usually is discovered after one or more episodes of dark or bloody urine in a person with no other symptoms of kidney disorder. Bloody urine may begin during or soon after a respiratory infection. Acute nephritic syndrome or nephrotic syndrome (groups of symptoms associated with decreased kidney functioning) may result.

Risk factors include having a personal or family history of IgA nephropathy or Henoch Schonlein purpura (a form of vasculitis that affects many parts of the body, and may cause a kidney lesion that is identical to the lesion of Berger's disease).

Berger's disease can occur in persons of all ages, but most often affects males in their teens to late 30s.

Symptoms:

changes in color of urine
- bloody
- urine dark, brown, or rust colored
repeated episodes of dark or bloody urine

Signs and tests:

There are no specific changes on physical examination. Occasionally, blood pressure may be elevated or swelling (edema) of the body may be present.

Urinalysis shows blood and red cell casts in the urine, and may also show protein and fats.
Kidney biopsy shows deposits of IgA antibodies and confirms the diagnosis.
Immunoelectrophoresis - urine shows antibodies to IgA.

Treatment:

The goal of treatment is to relieve symptoms and prevent or delay of chronic renal failure.

Antihypertensive medications and diuretics may be given to control high blood pressure and edema. Control of blood pressure is the most important measure to delay renal damage. Sodium (salt) and fluids may be restricted to control swelling. Low to moderate protein diet may be recommended in some cases.

Support Groups:

The stress of illness can often be helped by joining a support group where members share common experiences and problems. For this condition, see kidney disease - support group.

Expectations (prognosis):

IgA nephropathy progresses slowly. In many cases, it does not progress at all. High blood pressure, large quantities of protein in the urine, and increased BUN or creatinine levels (blood tests that reflect kidney functioning) indicate a higher risk for progression of the disorder. About 25% of people with IgA nephropathy develop end-stage renal failure within about 25 years.

Complications:

Calling your health care provider:

Call your health care provider if bloody urine develops or if urine output decreases.

Prevention:

There is no prevention known.

Review Date: 11/30/2001
Reviewed By: Andrew Koren, M.D., Department of Nephrology, NYU-Mount Sinai Medical Center, New York, NY. Review provided by VeriMed Healthcare Network.

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. Copyright 2003 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.